Abstract 81P
Background
Immunotherapies targeting the programmed cell death protein 1 (PD-1) to PD ligand 1 (PD-L1) checkpoint have improved prognosis in non-small cell lung cancer (NSCLC). PD-1/PD-L1 status has not been investigated in human immunodeficiency virus (HIV)-positive patients. This study sought to assess PD-L1 status and tumor immune-cell infiltration in NSCLC in HIV patients.
Methods
Consecutive HIV patients treated for NSCLC between 1996 and 2014 at Tenon hospital (Paris, France) were enrolled. PD-L1 tumor expression was assessed using immunohistochemistry (2 antibodies: L. Chen, clone 5H1 and Cell Signaling, clone E1L3N). Tumor immune cell infiltration was assessed for CD3 (SP7), CD4 (1F6), CD8 (C8/144b), CD20 (L26), CD163 (10D6) and MPO (59A5). The percentage of PD-L1- and immune-positive cells was ≥5%. The score used is the product of intensity (0, 1, 2 or 3) by positive cell percentage. The PD-L1 score was considered positive if >5. PD-L1 status and immune-cell infiltration results were compared to those of 54 NSCLCs from unknown HIV status patients.
Results
In total, 34 HIV-positive patients were evaluated: predominantly men (88.2%) with a median age of 51.1 years and adenocarcinomas (76.5%) with 38.2% stage IV. The median blood CD4 count was 480/µL (86-1120) and 64% exhibited undetectable viral load. The PD-L1 score was higher in HIV-positive patients (E1L3N clone: 0 [0-150] vs. 0 [0-26.7], p = 0.047; 5H1 clone: 0 [0-120] vs.0 [0-26.7] p = 0.66 respectively) whereas PD-L1 expression frequency did not differ between HIV-positive and HIV-undetermined patients (18.7% vs. 9.3% using E1L3N and 10% vs. 5.6% using 5H1, respectively). There was significantly greater CD8, CD20, and CD163 infiltration in the HIV-positive patients (Table).
| HIV-positive (n = 22) | HIV-undetermined (n = 54) | p-value | |||
|---|---|---|---|---|---|
| Median | Range | Median | Range | ||
| CD3 | 40 | 0-150 | 50 | 5-150 | 0.74 |
| CD4 | 20 | 0-120 | 26.7 | 0-60 | 0.76 |
| CD8 | 90 | 15-120 | 40 | 0-100 | ConclusionsThese results suggest that HIV–positive patients should feature in clinical trials assessing PD1/PD-L1 checkpoint inhibitors, and this score could be a better tool for the selection of patients that may benefit from immunotherapies. Clinical trial identificationLegal entity responsible for the studyAPHP, Tenon University Hospital, Paris, France FundingThis study received support from “CARDIF AO n°23 automne 2014” and from “Fonds de dotation 2015 Recherche en Santé Respiratoire AO automne 2015” DisclosureAll authors have declared no conflicts of interest. Resources from the same sessionZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|